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Abstract
The authors revise the concept of ALK-nega-
tive anaplastic large cell lymphoma (ALCL) in
the light of the recently updated WHO classifi-
cation of Tumors of Hematopoietic and Lym-
phoid Tissues both on biological and clinical
grounds. The main histological findings are il-
lustrated as well as the phenotypic, molecular
and clinical characteristics. Finally, the biolog-
ical rationale for possible innovative targeted
therapies is presented.
Introduction
Anaplastic large cell lymphoma (ALCL) is a
peripheral  T-cell  lymphoma  (PTCL),  repre-
senting around 2-3% of all lymphoid neoplasms,
according  to  the  World  Health  Organization
(WHO)  estimates.1,2 Originally  described  by
Stein et al. in 1985,3 it has undergone a series
of revisions, which have led to a more restric-
tive definition of the process.1,2,4,5 In particular,
two  different  entities  are  recognized  as  sys-
temic forms, the ALK+ and ALK- ALCL,1,2,6 the
former being characterized by the deregulated
expression of chimeric proteins expressing the
intracytoplasmic domain of the anaplastic lym-
phoma kinase (ALK) gene. Noteworthy, in the
last  edition  of  the  WHO  classification,  ALK-
ALCL was regarded as a provisional entity.1,2
However, emerging evidences suggest it repre-
sent  a  distinctive  condition.7 On  the  other
hand, differently from what initially reported by
Stein et al.,3 the cutaneous variant was recog-
nized as a different disease.8
Morphology
According  to  the  WHO  classification,  ALK-
ALCL, like the ALK+form, includes morphologic
variants: common, giant cell-rich, lympho-histi-
ocytic, and Hodgkin-like.1,2,9,10 All morpholog-
ical  variants  are  characterized  by  a  variable
proportion of large hallmark cells with eccen-
tric horse-shoe or kidney shaped nuclei). The
giant cell-rich type is characterized by several
multinucleated elements, often provided with
Reed-Sternberg-like  features  and  prominent
intra-sinusoidal  diffusion.1,5,11,12 The  lympho-
histiocytic variant displays a marked variability
of  the  neoplastic  cell  size  that  ranges  from
small to large. These are almost obscured by
abundant  reactive  histiocytes  with  eccentric
nuclei, a finding that can lead to a misdiag-
nosis of hyper-immune reaction.1,2,9,13-15 Inter-
estingly, transition from one histotype to the
other  is  at  times  recorded  within  the  same
node  (mixed  variant)  or  in  different  nodes
taken from the same patient at the time of di-
agnosis  or  in  relapse:  these  modifications
might correspond to intra-clonal modulation or
different  interaction  between  the  tumor  and
micro-environment.9,16 Finally,  the  so-called
ALCL of the Hodgkin-like type deserves special
attention.17 It  was  originally  described  as  a
form of the tumor, presenting in young people
with a bulky mediastinal mass and consisting
of  anaplastic  cells  arranged  in  nodules  sur-
rounded by sclerotic bands, as seen in nodular
sclerosing Hodgkin’s lymphoma (NSHL).17 Fol-
lowing the introduction of the REAL Classifica-
tion,5 which regarded it as a provisional entity,
such diagnosis was by no means also applied to
cases of aggressive HL that could not be easily
differentiated from ALCL, both on morphologic
and phenotypic grounds.5 This led to a diffuse
skepticism on the existence of such variant: it
was considered a basket more than an entity.
However, although rare, bona fide examples of
ALK- ALCL of the Hodgkin-like type can be en-
countered. These are characterized by homoge-
neous CD30-positivity, lack of CD15 and B-cell
activator protein (BSAP), variable expression
of T-cell antigens, CD45 and epithelial mem-
brane antigen (EMA), Epstein-Barr virus (EBV)
negativity and clonal TCR gene rearrangement.
Phenotype
Neoplastic cells of ALK- ALCL carry a distinc-
tive phenotypic profile irrespectively of the his-
totype.1,2,11,18They regularly express CD30,1-3,19
a glycoprotein of 120 kD carried by lymphoid
elements following activation. At immunohis-
tochemical  analysis,  the  antibodies  against
CD30  produce  different  types  of  positivity:
membrane-bound,  dot-like  in  the  Golgi  area
(corresponding to the accumulation of the 90
kD proteic precursor), and diffuse.19 The first
two  patterns  are  exclusive  of  lymphoid  ele-
ments with the exception of embryonic carci-
noma,19 while the third one can at times occur
in a variety of malignant tumors other than
lymphomas.19 Therefore,  the  immunopheno-
typic diagnosis of ALCL should always be based
on the application of a panel of antibodies, in-
cluding reagents anti-cytokeratins, melanoma-
associated antigens, CEA, and PLAP.1,2 In 60-
70% of cases, ALK- ALCL carries the EMA.9,20
CD3 expression is appreciated in about half
cases: it usually occurs at the cytoplasmic level
as expected in activated cells.9,21 CD3- tumors
may carry CD2, CD5 and/or CD7.9,11,21-23 The
expression of CD4 and CD8 is variable.9,11 Pos-
itivity for TIA-1, granzyme B and perforin is
recorded in most nstances. About 20% of ALCL
lack  CD45  and/or  express  CD15.9 Notably,
BSAP (i.e. the PAX5 gene product) is absent:24
its search represents a very useful tool for the
differentiation  of  ALK- ALCL  from  HL  and
DLBCL,  which  are  both  BSAP-positive.24 Fi-
nally, the search for EBV turns negative in ALK-
ALCLs both by in situ hybridization (ISH) and
immunohistochemistry: such negativity is re-
garded as one of the distinguishing features
between ALCL and HL in controversial cases.25
Molecular genetics
Recently, by using a comparative genomic
hybridization  (CGH)  platform,  Salaverria  et
al.26 identified  chromosomal  imbalances  in
65% of ALK- cases, within a cohort of 31 tu-
mors. In particular, gains of 1q and 6p21 were
more frequently observed.26 Interestingly, few
recurrent  chromosomal  imbalances  were
found in common with ALK+ ALCL (gains of 7
and  6q  and  13q  losses),  confirming  that  all
ALCLs  probably  share  common  pathogenetic
events (see below).
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As far as gene expression profiling (GEP) is
concerned, Thompson et al.27 initially demon-
strated the ability of GEP to correctly distin-
guish between ALK+ and ALK- ALCL based on
the analysis of their transcriptome and sug-
gested  that  some  pathogenetic  mechanisms
might be shared by these two entities, basing
on the common expression of certain genes in
both ALK+ and ALK- cases.
Subsequently, Lamant et al.28confirmed that
the different morphological variants as well as
ALK+ and  ALK- ALCL  could  be  distinguished
based  on  the  expression  of  specific  genes.
Specifically, ALK- ALCL were found to over-ex-
pression CCR7, CNTFR, IL22 and IL21.
Our group then included some ALCL in a
GEP study on PTCLs.29 Interestingly, we found
that ALCL can be roughly distinguished from
other PTCLs irrespectively of the ALK status,
confirming the idea of common pathogenetic
events. Finally, Piva et al.7 showed, that ALCL
are  molecularly  distinct  from  PTCL/NOS.  To
this regard, grippingly, a predictive analysis al-
lowed to identify 34 probe sets capable to dis-
tinguish ALCL from other PTCLs. Furthermore,
it  was  possible  to  clearly  differentiate  ALK+
and ALK- cases according to their GEPs, basing
on the expression of selected genes, including
GAS1, an ALK dependent molecule.7
More recently, Eckerle et al.23 studied iso-
lated cells from ALCL cases. Interestingly, the
analysis supported the derivation of ALCL from
activated T cells, though it was not possible to
identify  a  specific  counterpart.  Surprisingly,
only few genes were differentially expressed
between systemic and cutaneous ALCL despite
their different clinical behavior, and between
ALK- ALCL and classical Hodgkin lymphoma,
despite their different cellular origin.23
Clinical behavior
ALK- ALCL is an aggressive lymphoma which
frequently presents in advanced clinical stage
(III-IV) with B-symptoms, and extra-nodal in-
volvement,  as  other  PTCLs  do.11,30 Bone
marrow involvement is detected in up to 30% of
cases, being a relevant prognostic feature.31-33
Importantly,  ALCL  display  quite  different
clinical features depending on the expression
or not of the ALK protein.6,11,30,34-36ALK-tumors
are usually recorded among people aged 50-
70,6,11,30 and, most importantly, ALK+ has a sig-
nificantly better outcome than ALK- ALCL. In
particular,  up  to  90%  of  ALK+ ALCL  achieve
complete remission (CR) by adopting standard
antracyclin-containing regimens, and 70-80%
of  patients  were  actually  cured.6,11,30,34-36 By
contrast, only around 30-50% of ALK- cases ob-
tain stable CR by the same therapies,6,11,30sug-
gesting  that  more  aggressive  strategies  in-
cluding  autologous  or  allogeneic  bone-
marrow/stem cell transplantation may be nec-
essary.37
Noteworthy,  the  International  T-cell  lym-
phoma  project  have  recently  reported  that
ALK+ and ALK- ALCL seem to have a similar
prognosis (in terms of both FFS and OS), when
patients are stratified according to the clinical
parameters (i.e. age and/or stage). Grippingly,
this would suggest a prominent role for clinical
factors  in  determining  patients  outcome,
rather than for biological components.6
Notably, in the past years, it was suggested
that  the  distinction  between  ALK- ALCL  and
PTCL/NOS  was  of  limited  clinical  relevance,
only  age  and  the  International  Prognostic
Index (IPI) being of prognostic relevance in
these tumors.38 Nevertheless, it was recently
shown  that  clinical  differences  do  exist  be-
tween the two entities. In particular, in a large
international study, a greater proportion of pa-
tients  with  poor  performance  status  and  B-
symptoms,  but  a  lower  frequency  of  bone
marrow  invasion,  splenic  involvement  and
thrombocytopenia were observed in ALK- ALCL
as  compared  to  PTCL/NOS.6 Indeed,  in  this
study, ALK- ALCL showed an overall outcome
significantly better than PTCL/NOS.6
Targeted therapy
Importantly, as tyrosine-kinase deregulation
has been documented in several PTCLs,29,39-41
it is conceivable that ALK- ALCL might present
similar phenomenon as well, further studies
being indeed warranted.
Finally,  immunotherapy  strategies  could
represent  another  possible  therapeutic  ap-
proaches.  In  particular,  in  vitro and  in  vivo
studies showed that anti-CD30 antibodies in-
duce apoptotic cell death and tumor regression
in CD30+ lymphomas, including ALCL.42-46 In
addition,  other  studies  have  suggested  that
CD26  might  represent  a  promising  im-
munotherapeutic target.47
Conclusions
Although ALK- ALCL is still quoted as a pro-
visional entity, increasing evidences, both bio-
logical and clinical, suggest that it actually rep-
resent a tumor with distinctive features.
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